Most of the 5-year upside comes from filling new
qualified capacity into AI-optics demand, not from financial engineering. Fabrinet already trades at a premium for an EMS name, so I assume only modest multiple support from better mix, cleaner execution and slightly stickier commercial terms. That still supports low-end 2x equity value potential if the company turns capacity into durable program share.